252 related articles for article (PubMed ID: 32543261)
1. Beta-cell failure in type 2 diabetes: mechanisms, markers, and clinical implications.
Wysham C; Shubrook J
Postgrad Med; 2020 Nov; 132(8):676-686. PubMed ID: 32543261
[TBL] [Abstract][Full Text] [Related]
2. Incretins: their physiology and application in the treatment of diabetes mellitus.
Tasyurek HM; Altunbas HA; Balci MK; Sanlioglu S
Diabetes Metab Res Rev; 2014 Jul; 30(5):354-71. PubMed ID: 24989141
[TBL] [Abstract][Full Text] [Related]
3. Markers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes.
Jones AG; McDonald TJ; Shields BM; Hill AV; Hyde CJ; Knight BA; Hattersley AT;
Diabetes Care; 2016 Feb; 39(2):250-7. PubMed ID: 26242184
[TBL] [Abstract][Full Text] [Related]
4. Management of the T2D Patient With High A1C.
Frias JP; Wright E; Whitmire K
J Fam Pract; 2019 Nov; 69(9 Suppl):S1. PubMed ID: 32735306
[TBL] [Abstract][Full Text] [Related]
5. The entero-insular axis: implications for human metabolism.
Ranganath LR
Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
[TBL] [Abstract][Full Text] [Related]
6. Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme.
Mathieu C; Del Prato S; Botros FT; Thieu VT; Pavo I; Jia N; Haupt A; Karanikas CA; García-Pérez LE
Diabetes Obes Metab; 2018 Aug; 20(8):2023-2028. PubMed ID: 29603872
[TBL] [Abstract][Full Text] [Related]
7. Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?
Van Gaal LF; Gutkin SW; Nauck MA
Eur J Endocrinol; 2008 Jun; 158(6):773-84. PubMed ID: 18322302
[TBL] [Abstract][Full Text] [Related]
8. Sodium-glucose cotransporter-2 inhibition improves incretin sensitivity of pancreatic β-cells in people with type 2 diabetes.
Ahn CH; Oh TJ; Kwak SH; Cho YM
Diabetes Obes Metab; 2018 Feb; 20(2):370-377. PubMed ID: 28786557
[TBL] [Abstract][Full Text] [Related]
9. Fate of the beta-cell in the pathophysiology of type 2 diabetes.
Campbell RK
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S10-5. PubMed ID: 19801360
[TBL] [Abstract][Full Text] [Related]
10. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
Weng J
J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.
Kirk RK; Pyke C; von Herrath MG; Hasselby JP; Pedersen L; Mortensen PG; Knudsen LB; Coppieters K
Diabetes Obes Metab; 2017 May; 19(5):705-712. PubMed ID: 28094469
[TBL] [Abstract][Full Text] [Related]
12. Preoperative use of incretins is associated with increased diabetes remission after RYGB surgery among patients taking insulin: a retrospective cohort analysis.
Wood GC; Gerhard GS; Benotti P; Petrick AT; Gabrielsen JD; Strodel WE; Ibele A; Rolston DD; Still CD; Argyropoulos G
Ann Surg; 2015 Jan; 261(1):125-8. PubMed ID: 24646545
[TBL] [Abstract][Full Text] [Related]
13. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.
Thomas MK; Nikooienejad A; Bray R; Cui X; Wilson J; Duffin K; Milicevic Z; Haupt A; Robins DA
J Clin Endocrinol Metab; 2021 Jan; 106(2):388-396. PubMed ID: 33236115
[TBL] [Abstract][Full Text] [Related]
14. Predictors and Clinical Outcomes of Treatment Intensification in Patients With Type 2 Diabetes Uncontrolled on Basal Insulin in a Real-World Setting.
Kallenbach L; Shui AM; Cheng WY; Fan T; Hu W; Zichlin ML; Duh MS; Ye F; Levin PA
Endocr Pract; 2018 Sep; 24(9):805-814. PubMed ID: 29975575
[TBL] [Abstract][Full Text] [Related]
15. Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going.
DeFronzo RA
Am J Med; 2010 Mar; 123(3 Suppl):S38-48. PubMed ID: 20206731
[TBL] [Abstract][Full Text] [Related]
16. Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs.
Luo M; Kong X; Wang H; Zhai X; Cai T; Ding B; Hu Y; Jing T; Su X; Li H; Ma J
J Diabetes Res; 2020; 2020():6666403. PubMed ID: 33299890
[TBL] [Abstract][Full Text] [Related]
17. The effect of early insulin therapy on pancreatic β-cell function and long-term glycemic control in newly diagnosed type 2 diabetic patients.
Chon S; Oh S; Kim SW; Kim JW; Kim YS; Woo JT
Korean J Intern Med; 2010 Sep; 25(3):273-81. PubMed ID: 20830224
[TBL] [Abstract][Full Text] [Related]
18. beta-cell failure in diabetes and preservation by clinical treatment.
Wajchenberg BL
Endocr Rev; 2007 Apr; 28(2):187-218. PubMed ID: 17353295
[TBL] [Abstract][Full Text] [Related]
19. Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives.
Seino Y; Kuwata H; Yabe D
J Diabetes Investig; 2016 Apr; 7 Suppl 1(Suppl 1):102-9. PubMed ID: 27186364
[TBL] [Abstract][Full Text] [Related]
20. Impact of disease duration and β-cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon-like peptide-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trial.
Del Prato S; Frias JP; Blonde L; Aroda VR; Shehadeh N; Saremi A; Dex T; Niemoeller E; Souhami E; Liu M; Rosenstock J
Diabetes Obes Metab; 2020 Sep; 22(9):1567-1576. PubMed ID: 32323437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
